基于Cf DNA检测探索局部晚期食管鳞癌同期放化疗敏感性相关基因的初步研究

doi:10.3760/cma.j.cn113030-20210504-00185

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To explore the genes and molecular markers related to the sensitivity to concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Methods The peripheral blood sample of 31 patients with locally advanced esophageal squamous cell carcinoma receiving radical concurrent chemoradiotherapy was collected and the plasma circulating free DNA (cf-DNA) was extracted before treatment. The target gene capture sequencing technology based on NovaseQ6000high-throughput sequencing platform was employed to detect the changes of target genes and tumor mutation burden (TMB). According to the short-term efficacy of chemoradiotherapy, all patients were divided into the chemoradiotherapy-sensitive group (CR+PR) and chemoradiotherapy-resistant group (SD+PD). Bioinformatics and clinical data were adopted to analyze the differences of gene mutation and TMB between two groups. Results In the sequencing data of 31 patients, the tumor-related genes with a mutation frequency above 10% were Tp53, Notch1, BRAF, FGFR4, CDKN2A, ATRX and Axin2, which were almost equally distributed between the CR+PR and SD+PD groups. High-frequency mutant genes were associated with 7 signaling pathways, mainly involved in the RTK/RAS signaling pathways. The TMB value in the CR+PR group was higher than that in the SD+PD group (P=0.04), however, the mutation rate of GXYLT1 and KRT18 genes in the SD+PD group was higher than that in the CR+PR group (P<0.05). Conclusions Tp53, Notch1 and CDKN2A may be the high-frequency mutant genes associated with the incidence and progression of esophageal squamous cell carcinoma. KRT18, GXYLT1 and TMB are closely correlated with the sensitivity to concurrent chemoradiotherapy of patients with locally advanced esophageal squamous cell carcinoma.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Xiaofeng
	Liang Jun

Key words： Circulating free desoxyribonucleic acid Target gene Tumor mutation burden Chemoradiotherapy-sensitivity Esophageal neoplasm

Received: 04 May 2021

Corresponding Authors: Liang Jun, Email:liang23400@163.com

Cite this article:

Wang Xiaofeng,Liang Jun. Preliminary study of the detection of genes related to sensitivity to concurrent chemoradiotherapy based on circulating free DNA in locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 942-948.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20210504-00185 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I9/942

[1] 中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南(2020年版)[J]. 国际肿瘤学杂志,2020, 47(11):641-655.DOI:10.3760/cma.j.cn371439-20201015-00095.
Radiation Oncology Physicians Branch of Chinese Medical Doctor Association, Radiation Oncology Therapy Society of Chinese Medical Association, Oncology Radiation Therapy Professional Committee of Chinese Anti-Cancer Association.Radiotherapy guidelines for esophageal cancer in China (2020 ed)[J]. J Int Oncol, 2020, 47(11):641-655.DOI:0.3760/cma.j.cn371439-20201015-00095.
[2] Li BT, Janku F, Jung B, et al.Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers:results from the Actionable Genome Consortium[J]. Ann Oncol, 2019, 30(4):597-603.DOI:10.1093/annonc/mdz046.
[3] Cancer Genome Atlas Research.Integrated genomic characterization of oesophageal carcinoma[J]. Nature, 2017, 541(7636):169-175.DOI:10.1038/nature20805(2017).
[4] Dulak AM, Stojanov P, Peng S, et al.Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity[J]. Nat Genet, 2013, 45(5):478-486.DOI:10.1038/ng.2591.
[5] Song Y, Li L, Ou Y, et al.Identification of genomic alterations in oesophageal squamous cell cancer[J]. Nature, 2014, 509(7498):91-95.DOI:10.1038/nature13176.
[6] Chava S, Mohan V, Shetty PJ, et al.Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer[J]. Dis Esophagus, 2012, 25(1):81-87.DOI:10.1111/j.1442-2050.2011.01213.x.
[7] Makino T, Yamasaki M, Miyata H, et al.p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer[J]. Ann Surg Oncol, 2010, 17(3):804-811.DOI:10.1245/s10434-009-0786-9.
[8] Suzuki T, Yajima S, Ishioka N, et al.Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma[J]. Esophagus, 2018, 15(4):294-300.DOI:10.1007/s10388-018-0629-5.
[9] Lubin DJ, Mick R, Shroff SG, et al.The notch pathway is activated in neoplastic progression in esophageal squamous cell carcinoma[J]. Hum Pathol, 2018, 72(1):66-70.DOI:10.1016/j.humpath.2017.11.004.
[10] 徐瞳,胡丽娜,郭显智,等.5-氮杂胞苷可通过抑制Notch1通路诱导食管癌细胞凋亡[J]. 中国癌症杂志,2018, 28(10):726-732.DOI:10.19401/j.cnki.1007-3639.2018.10.002.
Xu T, Hu LN, Guo XZ, et al.5-azacytidine promotes apoptosis of esophageal cell lines through inhibiting Notch1 pathway[J]. Chin Oncol, 2018, 28(10):726-732.DOI:10.19401/j.cnki.1007-3639.2018.10.002.
[11] Jia R, Yang L, Yuan X, et al.GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation[J]. J Oncol, 2019, 2019:1621054.DOI:10.1155/2019/1621054.
[12] Tungekar A, Mandarthi S, Mandaviya PR, et al.ESCC ATLAS:A population wide compendium of biomarkers for Esophageal Squamous Cell Carcinoma[J]. Sci Rep, 2018, 8(1):12715.DOI:10.1038/s41598-018-30579-3.
[13] Miyawaki Y, Kawachi H, Ooi A, et al.Genomic copy-number alterations of MYC and FHIT genes are associated with survival in esophageal squamous-cell carcinoma[J]. Cancer Sci, 2012, 103(8):1558-1566.DOI:10.1111/j.1349-7006.2012.02329.x.
[14] Wang X, Niu H, Fan Q, et al.Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma[J]. Oncotarget, 2016, 7(17):24744-24751.DOI:10.18632/oncotarget.8271.
[15] Kwak AW, Lee MH, Yoon G, et al.Deoxypodophyllotoxin, a lignan from anthriscus sylvestris, induces apoptosis and cell cycle arrest by inhibiting the egfr signaling pathways in esophageal squamous cell carcinoma cells[J]. Int J Mol Sci, 2020, 21(18):6854.DOI:10.3390/ijms21186854.
[16] Yu Y, Guan H, Jiang L, et al.Nimotuzumab, anEGFR-targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma[J]. Int J Oncol, 2020, 56(4):945-956.DOI:10.3892/ijo.2020.4981.
[17] Indini A, Rijavec E, Grossi F.Circulating Biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC):a comprehensive review[J]. Cancers (Basel), 2021, 13(8):1794.DOI:10.3390/cancers13081794.
[18] Wang Z, Duan J, Cai S, et al.Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel[J]. JAMA Oncol, 2019, 5(5):696-702.DOI:10.1001/jamaoncol.2018.7098.
[19] Zhang B, Wang J, Liu W, et al.Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(12):2479-2487.DOI:10.1007/s00432-016-2253-x.
[20] Menz A, Weitbrecht T, Gorbokon N, et al.Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors:a tissue microarray study on 11,952 tumors[J]. Mol Med, 2021, 27(1):16.DOI:10.1186/s10020-021-00274-7.
[21] 杨召阳, 张红燕, 王丰, 等.细胞角蛋白(CK)7、CK8/18、CK19和p40在食管鳞状细胞癌中的表达及其与预后的关系[J]. 中华病理学杂志, 2018, 47(11):834-839.DOI:10.3760/cma.j.issn.0529-5807.2018.11.004.
Yang ZY, Zhang HY, Wang F, et al.Expression of cytokeratin (CK)7, CK8/18, CK19 and p40 in esophageal squamous cell carcinoma and their correlation with prognosis[J]. Chin J Pathol, 2018, 47(11):834-839.DOI:10.3760/cma.j.issn.0529-5807.2018.11.004.